Olipudase alfa

Seasoned executives bring deep cardiovascular clinical development experience and financial leadership as RTN-001 advances through Phase 2b clinical testing FALLS CHURCH, Va.--(BUSINESS WIRE)-- #CFO --Retension Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing RTN-001 for the treatment of hypertension, today announced that Alison D. Schecter, M.D., FACC, FCCP, and Alex Schwartz have joined the Company as Chief Medical Officer and Chief Financial Officer, respectively, as Retension advances RTN-001 through its ongoing Phase 2b trial. “Alison and Alex bring the caliber of leadership Retension needs as it advances RTN-001 through its ongoing Phase 2b trial,” said Eric Keller, Chief Executive Officer of Retension Pharmaceuticals. “Alison’s clinical development track record in the cardiovascular space is greatly respected among physicians and executives in our industry, and her experience overseeing registration-enabling programs will define RTN-001’s path forward. Alex has helped take companies through the full arc of value creation, from financing through clinical readouts to M&A transactions, and his perspective from both Wall Street and the corporate side will be invaluable as we build Retension for our next stage of growth. We are fortunate to have them both.” Alison D. Schecter, M.D. — Chief Medical Officer Dr. Schecter is a physician-scientist with board certifications in cardiology and internal medicine and has more than 25 years of expertise in cardiology and immunology, including deep experience in inflammation, cardiometabolic disease, and thrombosis. She joins Retension from Mineralys Therapeutics, Inc., where she served as Chief Development Officer and oversaw three registration trials in hypertension. Dr. Schecter completed her internal medicine training at Johns Hopkins and a Cardiology fellowship training at Massachusetts General Hospital. As an academic physician and tenured Associate Professor in Immunology and Medicine at Mount Sinai School of Medicine, Dr. Schecter built and served as co-founder of Mount Sinai School of Medicine’s Cardiovascular Research Institute. Dr. Schecter previously served as Chief Executive Officer of Molecules to Medicine Advisory Group, President of Research and Development at Axcella Health Inc., and Chief Medical Officer at Selecta Biosciences, Inc. At Sanofi-Genzyme, she was Global Project Head and Business Development liaison for Rare Diseases, playing a central role in the approval of Xenpozyme ® . As Head of Hemophilia Programs at Baxalta Incorporated, she led the approval of Adynovate ® . Dr. Schecter currently serves on the scientific advisory boards of Rapafusyn Pharmaceuticals, Inc. and Tectonic Therapeutic, Inc. “Cardiovascular disease remains the leading cause of death worldwide, and hypertension is the leading modifiable risk factor for cardiovascular mortality. RTN-001 represents a unique and differentiated approach, harnessing chemistry to enable a pleiotropic mechanism for patients in need with resistant hypertension, but without the electrolyte and patient tolerability issues that limit other agents,” said Dr. Schecter. “Having spent several years developing drugs in the hypertension and cardiometabolic development environment, I have a clear view of what it takes to deliver a registration-quality dataset, and I am excited to bring that experience to Retension as we approach the Phase 2b readout.” Alex Schwartz — Chief Financial Officer Mr. Schwartz is a seasoned finance executive with more than 15 years of experience both on the corporate side as well as on Wall Street as a biotechnology equity research analyst. He most recently served as Vice President of Financial Planning & Analysis and Investor Relations at Ventyx Biosciences, Inc., which was acquired by Eli Lilly and Company in March 2026. Prior to Ventyx, Mr. Schwartz held senior finance and investor relations roles at Allakos Inc., NGM Biopharmaceuticals, Inc. and Esperion Therapeutics, Inc. and provided financial and strategic leadership for Phase 2 and Phase 3 development, FDA and EMA approvals, and commercial launch. Earlier in his career, Mr. Schwartz was an equity research analyst at Stifel, Nicolaus & Company, where he covered cardiovascular and other therapeutic areas across the biotechnology sector. Mr. Schwartz holds a B.S. in Finance from Indiana University’s Kelley School of Business and an M.B.A. from Boston College’s Carroll School of Management. “With RTN-001 currently in a Phase 2b study for hypertension, Retension is at an important stage of growth and development,” said Mr. Schwartz. “I am honored to be part of the Retension team and look forward to helping the company achieve its strategic objectives and financial goals as we work to address the significant need for safe and effective therapies for patients with hypertension.” About Retension Pharmaceuticals Retension Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for the treatment of hypertension and other serious cardiovascular conditions. The company’s lead clinical candidate, RTN-001, is in development for patients with uncontrolled and resistant hypertension. About RTN-001 Retension Pharmaceuticals is developing RTN-001, a cardiovascular-targeted, next-generation PDE5 inhibitor designed to directly enhance nitric oxide signaling in central arteries that were previously inaccessible to first-generation PDE5 inhibitors, thereby addressing a core driver of hypertension. RTN-001 has been studied in multiple clinical trials in over 265 subjects. RTN-001 has a demonstrated efficacy and safety pro patients and healthy volunteers with clinically meaningful reductions in blood pressure. A Phase 2b study of RTN-001 in hypertension is ongoing. RTN-001 is being developed under an exclusive world-wide license from Sanofi S.A. For more information, please see Contacts Press and Investor Contact Alex Schwartz Chief Financial Officer aschwartz@retensionpharmaceuticals.com

今日核心看点 本期汇集顶刊科研突破、全国量子赛事落地、跨国量子制药合作、跨国药企 AI 重金布局及行业权威研判，覆盖分子生成算法、量子硬件材料、可合成分子设计多领域，全方位呈现量子技术与 AI 制药从基础研究走向产业落地的最新进展。 01 学术论文｜Nature Communications 刊发浙江大学 LaMGen：大模型驱动多靶点 3D 分子生成新框架 近日，浙江大学侯廷军、康玉教授团队联合澳门理工大学刘焕香教授团队，在《Nature Communications》发表重磅研究，推出基于大语言模型的多靶点药物通用 3D 分子生成框架 LaMGen。该框架仅输入靶蛋白氨基酸序列，即可直接生成具备量子力学精度的 3D 活性分子，在双靶点、三靶点复杂药物设计场景中性能优势突出。团队同步构建 MTD2025 大规模数据集，收录超 60 万个量子力学精度 3D 分子构象、44.6 万条双靶点及 28.3 万条三靶点关联数据，为复杂疾病多靶点创新药研发提供全新底层计算工具。 02 产业动态｜第三届 “五岳杯” 量子计算挑战赛总决赛落地苏州，生物制药赛道成果亮眼 5 月 7 日，第三届 “五岳杯” 量子计算挑战赛总决赛于苏州金鸡湖国际会议中心正式举办。立足十五五规划量子科技未来产业战略定位，赛事依托移动云五岳纪元量子计算云平台，覆盖通信安全、金融风控、生物制药、电力调度等核心赛道。大赛汇聚全国 1182 支参赛队伍、超 3000 名科研从业者参赛，最终 10 支顶尖高校队伍晋级总决赛同台竞技。其中天津医科大学带来量子优化乳腺癌转移多组学标志物预测模型，湖南农业大学推出基于相干伊辛机的药物逆向设计方案，展现量子计算在生物医药研发场景的落地潜力。 03 AI 制药｜赛诺菲斥资 2.94 亿美元扩建多伦多 AI 卓越中心，全链路提速新药研发 5 月 6 日，赛诺菲官宣投入 2.94 亿美元加码扩建多伦多 AI 卓越中心，同步获得安大略省投资基金最高 500 万美元配套拨款，计划 2028 年前新增 50 个 AI 与数据科学专业岗位。目前该中心已组建超 150 人专业团队，覆盖云计算、数据工程、生物信息学、制药数据科学等全链条领域。赛诺菲已将 AI 深度融入新药发现、临床开发、生产上市及全周期管理；依托 AI 构建的数字孪生虚拟患者模型，助力酶替代疗法 Xenpozyme 斩获 FDA 儿科适应症，成为 AI 赋能药物商业化落地标杆案例。 04 国际合作｜Qubit Pharmaceuticals 牵手新加坡 CQT，联合攻坚量子药物发现核心算法 5 月 2 日，据量子行业媒体 Quantum Computing Report 报道，新加坡量子技术中心（CQT）与量子制药企业 Qubit Pharmaceuticals 开启为期两年战略合作，聚焦分子发现领域新型量子算法研发与落地。双方已在 Quantinuum H2、Helios 捕获离子系统上，首次实现量子马尔可夫链蒙特卡洛算法实验落地，相较经典算法有望实现二次运算加速，相关成果收录于 arXiv 预印本（ID:2603.08395）。同时团队持续迭代变分量子本征求解器、量子相位估计等前沿算法，推动量子计算深度融入药物研发早期决策流程。 05 学术论文｜arXiv 修订量子启发强化学习框架，破解可合成分子设计瓶颈 5月6日，Dannong Wang 团队相关论文（arXiv:2409.09183v2）完成版本修订，提出量子启发模拟退火策略神经网络强化学习新方法。研究融合确定性 REINFORCE 算法输出转移概率、遗传算法局部搜索双重机制，可高效探索海量化学空间，同时严格保障生成分子的实际合成可行性。经 PMO 基准框架全面评测，该方案在可合成分子优化任务中，性能显著优于传统遗传算法等主流方法，为 AI + 量子驱动的苗头化合物设计提供全新技术路径。 06 学术成果｜Nature Communications 刊发拓扑超导材料调控新方法，筑牢量子硬件量产根基 2 月 25 日，《Nature Communications》刊发芝加哥大学普利兹克分子工程学院联合西弗吉尼亚大学研究成果，研发出简易化学调控工艺，通过精准调控超薄薄膜中碲、硒元素配比，大幅降低拓扑超导体制备门槛。拓扑超导体凭借拓扑态稳定、抗噪声干扰优势，是下一代量子计算硬件核心候选材料。该研发方案将超导薄膜最高工作温度提升至 13 开尔文，远超传统铝基平台 1 开尔文临界值，为大规模制备高稳定性量子计算硬件提供低成本实用方案，相关成果近期经 ScienceDaily 转载引发行业关注。 07 产业观察｜北京量子院发布深度研判：量子计算生命科学应用处于成长临界点 5 月 6 日，北京量子信息科学研究院（BAQIS）发布量子计算生命科学应用行业深度分析。文章解读 Wellcome Leap Q4Bio 赛事风向：200 万美元奖项花落量子药物模拟团队，500 万美元头奖因现有硬件性能不足空置，凸显量子计算生物医药应用机遇与挑战并存。当前量子计算在物理、化学领域已落地初见成效，生物学应用仍处于起步培育阶段。全球科研团队正提前布局适配下一代量子硬件的算法与研发工作流，静待硬件成熟实现无缝落地；Wellcome Leap 也计划推出接续项目，持续加码量子与生物交叉赛道布局。